Core Viewpoint - The company, Genting New Year (01952.HK), has noted the approval of a generic version of its patented product Budesonide Enteric Capsules (耐赋康®) by the National Medical Products Administration of China, while emphasizing the protection of its original product under a valid patent until May 7, 2029 [1] Group 1 - The company’s original product,耐赋康®, is protected by patent ZL200980127272.5, which is currently valid [1] - The patent rights will expire on May 7, 2029, and the company has registered relevant patent information on the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must obtain legal permission from the company before manufacturing, using, or selling products that fall under the patent protection before its expiration [1] Group 2 - The company reserves the right to take legal action against any infringement of the patent rights or violations of commitments made by generic drug applicants [1] - Generic drug applicants must adhere to their commitments if they submit a "Category 3 Declaration," promising not to market the drug before the patent expires [1]
云顶新耀(01952.HK)：耐赋康®相关技术在中国受专利保护 且处于有效状态